Category Archives: Biotechnology

Mystic moldy pizza: Food for thought from Allicense 2014

SAN FRANCISCO – When talking trends in biopharma there’s no shortage of metaphors – Tuesday’s health care debate, for example, went for the timely baseball terms, referencing singles and home runs – or oft-overused industry buzzwords, of which the recent…

Share

An Asia Strategy is Not Optional

“If you plan to be around five or 10 years from now, you have to have a Chinese strategy.” That poignant comment in a BioWorld Today article came from Joshua Boger in 2011. The founder and former CEO of Vertex…

Share

A $100B Market Cap: Now That’s a Big Deal for Biotech

Remember the heady days about eight years ago when Amgen Inc. and Genentech Inc., prior to its acquisition by Basel, Switzerland-based Roche AG, both vied for top spot in terms of market capitalization? At that time, both companies briefly commanded…

Share

Bubbleology and Biotech’s Bull Run

Our recent analysis of biotech’s second quarter performance showed, for public biotech companies at least, their bull run that began more than 18 months ago is showing no signs of slowing down. Since the beginning of 2012 the Nasdaq Biotechnology…

Share

Oh, Give it Iressa! Nope: ‘Bad Pharma’ Firms Need to Tell More

So urgently did I think I wanted to read Ben Goldacre’s Bad Pharma, that I ordered it from Amazon’s UK site last November, unwilling to wait for U.S. publication – which happened just as I reached the end, polishing off…

Share

BioWorld’s 6th Annual Holiday Gift Guide

It’s that time of year, when some thoughts turn to sugar plum fairies and others to the J.P. Morgan Healthcare Conference – or JPM#13 as it’s now widely known. Before you pop the cork on another New Year, however, it’s…

Share

FDA’s Confusing Action Against Burzynski – What Does it Really Mean?

Last month the FDA’s Office of Prescription Drug Promotion (OPDP) issued a warning letter to the Burzynski Research Institute Inc. and the Burzynski Clinic regarding claims made for its antineoplastons A10 and AS2-1 injections that violate the Federal Food, Drug,…

Share

The Times They Are A-Changin’

Kudos to the folks at Biotechnology Industry Organization (BIO) for selecting the industry’s “hot button” issues for panel discussions at the annual BIO Investor Forum (BIF) just concluded in San Francisco. In years past it has been my experience that…

Share

What Global Financial Crisis? Capital Markets Back Biotechs

It is that time of year again when we take the pulse of the industry at the close of the third quarter. Overall we find that it is performing well, more so for public biotechs than private ones. Despite the…

Share

Life Isn’t as Sweet as it May Seem in Biotech’s C-Suites

Biotechnology is an idiosyncratic industry in which some executives can stake their careers on the pursuit of orphan drugs that, at best, will offer only limited opportunity for corporate profits and investors returns, while addressing the usually unmet needs of…

Share